Online citations, reference lists, and bibliographies.
← Back to Search

Pharmacokinetics And Biodistribution Of The Camptothecin–polymer Conjugate IT-101 In Rats And Tumor-bearing Mice

Thomas Schluep, J. Cheng, K. Khin, M. Davis
Published 2005 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Purpose: IT-101 is a camptothecin–polymer conjugate prepared by linking camptothecin (CPT) to a hydrophilic, cyclodextrin-based, linear polymer through ester bonds. In previous studies, these polymer conjugates with high molecular weights (ca 90 kDa) have shown significant antitumor effects against human colon carcinoma xenografts. The pharmacokinetics of IT-101 in plasma of rats and its biodistribution in nude mice bearing human LS174T colon carcinoma tumors is reported here. Methods: Sprague–Dawley rats were injected intravenously with three different doses of IT-101. Serial plasma samples were analyzed for polymer-bound and unconjugated CPT by high-performance liquid chromatography (HPLC). Concentration vs time data were modeled using non-compartmentalized methods and compared to CPT alone injected intravenously at an equivalent dose. Tumor-bearing mice were injected intravenously with IT-101 and intraperitoneally with CPT alone, and sacrificed after 24 and 48 h, and serum, heart, liver, spleen, lungs and tumor collected. Tissue samples were extracted and analyzed for polymer-bound and unconjugated CPT by HPLC. Results: Plasma concentrations and the area under the curve for polymer-bound CPT are approximately 100-fold higher than those of unconjugated CPT or CPT alone, injected intravenously at an equivalent dose. The plasma half-life of IT-101 ranges from 17 -20 h and is significantly greater than that of CPT alone (1.3 h). When CPT is conjugated to polymer, the biodistribution pattern of CPT is different from that taken alone. At 24 h post injection, the total CPT per gram of tissue is the highest in tumor tissue when compared to all other tissues tested. Tumor concentrations of active CPT released from the conjugate are more than 160-fold higher when administered as a polymer conjugate rather than as CPT alone. Conclusions: The studies presented here indicate that intravenous administration of IT-101, a cyclodextrin based polymer–CPT conjugate, gives prolonged plasma half-life and enhanced distribution to tumor tissue when compared to CPT alone. The data also show that active CPT is released from the conjugate within the tumor for an extended period of time. These effects likely play a significant role in the enhanced antitumor activity of IT-101 when compared to CPT alone or irinotecan.
This paper references
Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs.
C. Conover (1999)
Camptothecin and its analogs. An overview of their potential in cancer therapeutics.
F. Muggia (1996)
10.1038/sj.bjc.6601922
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
D. Bissett (2004)
10.1016/S0168-3659(01)00323-6
Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo.
J. Singer (2001)
10.1152/AJPCELL.1979.236.3.C103
The generation of electric currents in cardiac fibers by Na/Ca exchange.
L. Mullins (1979)
Phase I andpharmacokinetic studyofDE - 310 inpatients with advanced solid tumors
O Soepenberg (2005)
10.3892/IJO.18.2.331
Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice.
Y. Zou (2001)
Drug Delivery Systems
J. E. Guillet (1995)
10.1007/s00280-003-0685-x
Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma
N. Sarapa (2003)
Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy.
M. Zamai (2003)
10.1016/S0968-0896(98)00005-4
Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity.
R. Greenwald (1998)
10.1111/J.1749-6632.1996.TB26391.X
Camptothecin and Its Analogs
F. Muggia (1996)
10.1158/1078-0432.CCR-04-1756
MEN4901/T-0128, a New Camptothecin Derivative–Carboxymethyldextran Conjugate, Has Potent Antitumor Activities in a Panel of Human Tumor Xenografts in Nude Mice
F. Fujita (2005)
10.1200/JCO.2003.03.143
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
E. Rowinsky (2003)
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.
F. Muggia (1972)
Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.
P. Creaven (1972)
10.1021/JM020022R
Synthesis and in Vivo Antitumor Activity of Poly(l-glutamic acid) Conjugates of 20(S)-Camptothecin
R. Bhatt (2003)
10.1021/JA00968A057
Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2
M. Wall (1966)
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
O. Soepenberg (2005)
10.1152/AJPRENAL.1979.236.2.F103
Use of flexible polymers as probes of glomerular pore size.
K. Jørgensen (1979)
10.1021/MP049966Y
Antitumor Activity of β-Cyclodextrin Polymer−Camptothecin Conjugates
Jianjun Cheng (2004)
10.1021/BI00437A018
On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex.
R. Hertzberg (1989)
10.1021/BC0340924
Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates.
J. Cheng (2003)
10.1158/1078-0432.CCR-04-1758
Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors
O. Soepenberg (2005)
10.1021/JM9600555
Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms.
R. Greenwald (1996)
10.1038/sj.bjc.6601811
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours
F. M. Wachters (2004)
Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.
Creaven Pj (1972)
2005)Phase I andpharmacokinetic studyofDE-310 inpatients with advanced solid tumors
O Soepenberg (2005)
10.1021/BI00200A013
Differential interactions of camptothecin lactone and carboxylate forms with human blood components.
Z. Mi (1994)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
Water-soluble poly-(L-glutamic acid)-Glycamptothecin conjugates enhance camptothecin stability and efficacy in vivo Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors
Jw Singer (2001)
10.1097/00001813-200102000-00002
Modulation of camptothecin analogs in the treatment of cancer: a review
D. Kehrer (2001)
Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.
C. Moertel (1972)
10.1016/S0168-3659(99)00243-6
Polymer-bound camptothecin: initial biodistribution and antitumour activity studies.
V. R. Caiolfa (2000)
10.1039/B410799N
Synthetic polymers as drugs and therapeutics
Beverley R Twaites (2005)
10.1023/A:1018919224450
Plasma Pharmacokinetics of the Lactone and Carboxylate Forms of 20(S)-Camptothecin in Anesthetized Rats
D. Scott (2004)



This paper is referenced by
10.1081/E-EBPPC-120052058
Anticancer Agents: Polymeric Nanomedicines
R. Tong (2017)
10.4143/crt.2009.41.1.1
Advances of cancer therapy by nanotechnology.
X. Wang (2009)
10.1039/c8bm00726h
Low-intensity focused ultrasound (LIFU)-activated nanodroplets as a theranostic agent for noninvasive cancer molecular imaging and drug delivery.
J. Liu (2018)
10.1016/j.nano.2011.09.007
Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.
Shikha Gaur (2012)
10.1007/978-1-4614-9434-8_5
Polymer–Drug Conjugate in Focal Drug Delivery
R. Swami (2014)
10.1007/978-1-4614-7876-8_8
Tumor Vasculature, EPR Effect, and Anticancer Nanomedicine: Connecting the Dots
S. Taurin (2013)
10.1016/j.jconrel.2012.07.013
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
S. Taurin (2012)
10.1080/09205063.2017.1406632
Camptothecin prodrug nanomicelle based on a boronate ester-linked diblock copolymer as the carrier of doxorubicin with enhanced cellular uptake
Y. Gao (2018)
10.1016/j.nano.2015.10.020
Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.
Shizhu Chen (2016)
10.1073/pnas.1309566110
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle
S. Eliasof (2013)
10.3390/POLYM6082186
Impact of the Enhanced Permeability and Retention (EPR) Effect and Cathepsins Levels on the Activity of Polymer-Drug Conjugates
Amit Kumar Rajora (2014)
10.1016/j.jconrel.2016.12.023
Safe approaches for camptothecin delivery: Structural analogues and nanomedicines
Pablo Botella (2017)
10.1039/b920570p
PEGylated polymers for medicine: from conjugation to self-assembled systems.
Maisie J. Joralemon (2010)
10.1016/j.addr.2007.11.009
Polymer-drug conjugates: recent development in clinical oncology.
Chun Xing Li (2008)
10.1016/J.JSSC.2010.05.035
Synthesis and release behavior of composites of camptothecin and layered double hydroxide
Lun Dong (2010)
10.1016/j.biomaterials.2010.01.009
The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells.
R. Tong (2010)
10.1002/anie.201403036
Engineered nanoparticles for drug delivery in cancer therapy.
T. Sun (2014)
10.1021/MA202581D
Drug-Initiated, Controlled Ring-Opening Polymerization for the Synthesis of Polymer-Drug Conjugates.
R. Tong (2012)
10.1002/adma.201704307
Biodistribution, Clearance, and Long-Term Fate of Clinically Relevant Nanomaterials.
Joël Bourquin (2018)
10.1158/1078-0432.CCR-08-2619
Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models
T. Numbenjapon (2009)
10.2174/138161211798194530
Recent advances in the design and synthesis of prednisolone and methylprednisolone conjugates.
Eliška Bílková (2011)
10.18632/oncotarget.9878
Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis
C. Lin (2016)
10.1016/j.biomaterials.2015.02.122
Targeted tumor theranostics using folate-conjugated and camptothecin-loaded acoustic nanodroplets in a mouse xenograft model.
Wei-Tsung Chen (2015)
10.1016/j.jconrel.2011.03.007
Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Sonke Svenson (2011)
Prodrug approaches to reduce treprostinil toxicity
Christina Picken (2019)
10.1016/j.molmed.2010.08.001
Small-molecule delivery by nanoparticles for anticancer therapy.
Z. Chen (2010)
10.1016/j.jconrel.2011.06.039
Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation.
P. Botella (2011)
10.1016/j.omtn.2017.10.019
A Novel Therapeutic Strategy for Cancer Using Phosphatidylserine Targeting Stearylamine-Bearing Cationic Liposomes
M. De (2018)
10.1016/j.carbpol.2020.116401
Cyclodextrin as a magic switch in covalent and non-covalent anticancer drug release systems.
Bingren Tian (2020)
10.1158/1078-0432.CCR-05-1566
Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models
Thomas Schluep (2006)
10.1039/c6sc00970k
Dual-channel NIR activatable theranostic prodrug for in vivo spatiotemporal tracking thiol-triggered chemotherapy† †Electronic supplementary information (ESI) available: Detailed experimental procedures, characterizations, supplementary optical spectra and figures. See DOI: 10.1039/c6sc00970k
M. Ye (2016)
10.1124/jpet.110.168294
Camptothecin Attenuates Cytochrome P450 3A4 Induction by Blocking the Activation of Human Pregnane X Receptor
Yakun Chen (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar